

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A vaccine composition suitable for administration to a subject, said composition comprising an antigen bearing target and a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which can bind to a carbohydrate

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide of a leukocyte,

wherein said vaccine composition includes ~~comprises~~ said fusion polypeptide bound to a carbohydrate on said antigen bearing target and ~~further comprises some of~~ includes said polypeptide which is not bound to said antigen bearing target.

2. (Currently amended) The ~~vaccine~~ composition of claim 1, wherein said ligand is chosen from the group: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule, a ligand for an opsonin receptor.

3. (Withdrawn) The vaccine composition of claim 2 wherein said ligand comprises at least five contiguous amino acids of a naturally occurring cytokine, said cytokine being chosen from the group: GM-CSF, an interleukin, a chemokine, an interferon, a TNF-alpha, a flt-3 ligand.

4. (Withdrawn) The vaccine composition of claim 2 wherein said ligand comprises at least about five contiguous amino acids of a naturally occurring CD154 molecule.

5. (Currently amended) The ~~vaccine~~ composition of claim 1, wherein said antigen bearing target is chosen from the group: a tumor cell, a virus, a bacterial cell, a

fungal cell, a cell of a parasite, a prion, a mammalian cell, an insect cell, a polypeptide free of other cell-derived material.

6. (Currently amended) The ~~vaccine~~ composition of claim 5, wherein said antigen bearing target is pathogenic.

7. (Currently amended) The ~~vaccine~~ composition of claim 5, wherein said antigen bearing target is attenuated.

8. (Currently amended) The ~~vaccine~~ composition of claims 1, wherein said antigen bearing target is a cell which is substantially unable to divide.

9. (Currently amended) The ~~vaccine~~ composition of claims 1, wherein said leukocyte is an antigen presenting cell.

10. (Currently amended) The ~~vaccine~~ composition of claim 9, wherein said leukocyte is a professional antigen presenting cell.

11. (Currently amended) The ~~vaccine~~ composition of claim 9, wherein said leukocyte is a dendritic cell.

12. (Currently amended) The ~~vaccine~~ composition of claim 1, wherein said first amino acid sequence can bind to a sialic acid on a glycoprotein.

13. (Currently amended) The ~~vaccine~~ composition of claim 1, wherein said first amino acid sequence comprises a carbohydrate-binding domain of a naturally occurring lectin.